Core Insights - HeartFlow initiated revenue guidance for 2026 at $218 million to $222 million, indicating a year-over-year growth of approximately 24% to 26% [1] - The company reported a fourth-quarter revenue of $49.1 million, reflecting a 40% increase year over year, with U.S. revenue at $44.8 million, up 41% [3][7] - Non-GAAP gross margin for the quarter reached nearly 80%, an improvement from 75.3% in the previous year, attributed to volume leverage and AI-driven efficiencies [2][7] Revenue and Growth Projections - Management expects plaque revenue to contribute approximately $15 million to $17 million in 2026, with a significant portion anticipated in the second half of the year [1][6] - The company guided for a non-GAAP gross margin of 80% to 81% for 2026, representing an expansion of roughly 300 to 400 basis points year over year [1][7] Product and Innovation Pipeline - HeartFlow is set to launch PCI Navigator in April 2026, an AI-driven planning tool for interventional cardiologists, and will roll out HeartFlow Autonomous Processing starting late 2026 [5][15][17] - The company has a proprietary database of 160 million annotated CT images, which supports its innovation efforts and has led to an increase in the midterm non-GAAP gross margin target to 85% [5][17] Market Expansion and Adoption - The company reported strong early momentum in Plaque Analysis, ending 2025 with 489 accounts, supported by a new Category One CPT code effective January 1, 2026 [6][10] - HeartFlow estimates an incremental $6 billion U.S. opportunity by expanding into a high-risk asymptomatic population, raising the total market opportunity to $11 billion [19] Competitive Positioning - HeartFlow differentiates itself through its proprietary data set, clinical evidence base, and integration into clinical workflows, competing on product quality rather than price [20] - The company has seen durable utilization of its FFRct technology, with new accounts typically reaching steady state within about a year [8] Financial Position - HeartFlow ended the quarter with $280.2 million in cash, equivalents, and investments, positioning the company to fund operations through profitability while investing in R&D and commercial expansion [22]